SLC5A2 and diabetic kidney disease: The relative RR in kidney disease progression with SGLT2 inhibitors across the four trials was similar when analyzed separately by primary kidney diagnosis (diabetic kidney disease or nephropathy, ischemic and hypertensive kidney disease, glomerular disease, and other/unknown).